juillet 28, 2023
The federal department will assess Canadian and international data that looks at the risk of suicidal thoughts, self-harm and suicide when it comes to GLP-1 receptor agonists. The review follows similar actions by health agencies in Europe and the U.K. While Health Canada didn't say which brand-name medications are included in its review, the following will likely be under consideration, along with Ozempic:
- Novo Nordisk's Wegovy;
- AstraZeneca's drug for Type 2 diabetes, exenatide, which is marketed as Bydureon;
- Eli Lilly's dulaglutide, marketed as Trulicity;
- Sanofi's lixisenatide; and
- Sanofi's Soliqua.
Related:
Santé Canada évalue le diabète populaire et les médicaments amaigrissants comme Ozempic pour le risque de suicide - Radio-Canada
Lire l'article